Daré Bioscience awarded $10M from ARPA-H to develop HPV treatment candidate DARE-HPV

Dare Bioscience, Inc.

Award of $10M from ARPA-H Sprint for Women's Health; milestone-based payments over 24 months.
DARE-HPV: investigational fixed-dose lopinavir/ritonavir vaginal insert for HPV-related cervical diseases.
Milestones include IND-enabling studies, FDA IND clearance, clinical supplies, and Phase 2 trial start.
More than half of award payable in first 12 months; ARPA-H retains certain IP rights including march-in.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.